Source facts
FDA issued an approval letter for BOSULIF on 2026-03-04. The source metadata identifies NDA 203341 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
BOSULIF — FDA Approval Letter (NDA 203341)
Issued to PF PRISM CV. Application is approved as submitted.
Assyro regulatory brief
FreeWhat did FDA decide for BOSULIF?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 203341.
- 3Submission: supplement.
- 4Sponsor: PF PRISM CV.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the BOSULIF approval letter
Is BOSULIF FDA approved?
This letter documents an FDA approval action: FDA approved NDA 203341 for BOSULIF, sponsored by PF PRISM CV, on March 4, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 203341?
NDA 203341 is the application under which FDA issued this approval letter for BOSULIF to PF PRISM CV. The letter is dated March 4, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.